a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
Clinical trial NCT04782193 · UNKNOWN
Trial details
- NCT number
- NCT04782193
- Sponsor
- Chongqing Precision Biotech Co., Ltd
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-23
- Primary completion
- 2023-12-31
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.